Evolent Health, INC 8-K filings

Evolent Health announced second quarter 2026 results, showcasing significant revenue growth and providing an optimistic 2027 outlook with projected revenue increases exceeding 25%.

Evolent Health announced its first quarter 2026 financial results, reporting increased revenue and a reduced net loss, while reaffirming its full-year guidance.

Evolent Health announced its fourth quarter and full year 2025 financial results, reporting a significant net loss driven by goodwill impairment, despite growth in adjusted EBITDA and a strong 2026 revenue outlook.

Evolent Health, Inc. announced the completion of its previously disclosed stock purchase agreement with Privia Management Company, LLC.

Evolent Health announces a new independent director appointment to its Board and reaffirms its fourth quarter 2025 revenue and Adjusted EBITDA guidance.

Evolent Health reported strong third-quarter 2025 financial results, exceeding expectations, and announced significant leadership team restructuring to support accelerating growth.

Evolent Health announced the strategic divestiture of its Evolent Care Partners business for up to $113 million, reaffirming its Q3 and full-year 2025 financial guidance.

Evolent Health, Inc. completed a private placement of $166.75 million in 4.50% convertible senior notes due 2031, using proceeds to repurchase existing 2025 notes and Class A common stock.

Evolent Health priced an upsized $145 million convertible senior notes offering due 2031 to repurchase existing 2025 notes and Class A common stock.

Evolent Health announced a proposed $140 million convertible senior notes offering to repurchase existing debt and common stock, alongside disclosing a Department of Justice False Claims Act investigation.

Evolent Health reported strong second-quarter adjusted EBITDA, surpassing targets and raising its full-year profitability guidance, despite a decline in GAAP revenue and net income.

Evolent Health, Inc. reaffirmed its full-year and second-quarter 2025 Adjusted EBITDA guidance, citing lower-than-expected oncology costs, and secured an incremental non-dilutive debt facility to address its 2025 Convertible Notes and support accelerated organic growth.

Evolent Health, Inc. disclosed the successful election of all ten director nominees, ratification of its independent auditor, approval of executive compensation, and an amendment to its incentive plan, alongside a significant reconstitution of its Board committees following its 2025 Annual Meeting.

Evolent Health, Inc. announced it will reaffirm its previously issued 2025 full-year and second-quarter revenue and Adjusted EBITDA guidance during its presentation at the William Blair 45th Annual Growth Stock Conference.

Evolent Health reports Q1 2025 financial results, achieving the high end of expectations and reiterating its full-year 2025 revenue and Adjusted EBITDA outlook.

Evolent Health nominates Shawn Guertin, former CFO of CVS Health and Aetna, to its Board of Directors as Diane Holder will not stand for re-election at the upcoming annual meeting.

Evolent Health reports revenue growth of 16.3% for Q4 2024 and 30.1% for the full year, alongside strategic contract amendments aimed at boosting future profitability.

Evolent Health and Engaged Capital enter into a cooperation agreement, resulting in the appointment of Brendan Springstubb to Evolent's Board of Directors and other governance changes.

Evolent Health plans to borrow $200 million in delayed draw term loans for general corporate purposes, including working capital and managing future liabilities.

Evolent Health outlines its strategy for growth and profitability in the specialty condition management sector, addressing both anticipated headwinds and company-specific tailwinds at the J.P. Morgan Healthcare Conference.

Evolent Health has amended its credit agreement to include an additional $250 million in secured debt financing, consisting of a revolving credit facility increase and two new term loan facilities.

Evolent Health reported a revenue increase of 21.6% year-over-year for Q3 2024, but experienced a net loss and revised its Adjusted EBITDA outlook due to higher medical costs.

Evolent Health announced a 37.9% year-over-year revenue increase for the second quarter of 2024, while also narrowing its full-year revenue outlook and updating its Adjusted EBITDA guidance.

Evolent Health's 2024 annual meeting saw the election of ten directors, ratification of Deloitte & Touche LLP as auditor, and approval of executive compensation.

Evolent Health is set to acquire certain assets from Machinify, including a perpetual license to its AI platform, to enhance its specialty condition management platform.

Evolent Health announced a 49.6% year-over-year revenue increase for the first quarter of 2024, along with an improved full-year revenue outlook.

Evolent Health announced a 45% increase in full-year revenue for 2023, alongside significant growth in adjusted EBITDA and a positive outlook for 2024.

Evolent Health has appointed Russell Glass, CEO of Headspace, to its Board of Directors, succeeding Dr. Tunde Sotunde who recently retired.